JAN 26 2006

K052442

1/2

510(k) SUMMARY

Radiancy (Israel) Ltd.'s Radiancy SkinStation® with Modified Light Unit Assembly for Psoriasis Treatment

Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared

Manufacturer:

Radiancy (Israel) Ltd.
9 Gan Rave Street
Industrial Park
Yavne
Israel
Telephone: +972-8-9438010
Facsimile: +972-8-9438020

Contact Person:

Margaret R. Fourte
Director, Clinical and Regulatory Affairs
Radiancy, Inc.
40 Ramland Road, Suite 10
Orangeburg, NY 10962
Telephone: (845) 398-1647
Facsimile: (845) 398-1648
Email: margaret@radiancy.com

Date Prepared: September 2, 2005

Name of Device and Name/Address of Sponsor

Trade/Proprietary Name: Radiancy SkinStation® with Modified LUA

Common Name: Pulsed Light System and Light Unit Assembly

Classification Name: Laser surgical instrument for use in general and plastic surgery and in dermatology (21 C.F.R. § 878.4810)

Manufacturing Facility:

Radiancy (Israel) Ltd.
9 Gan Rave Street
Industrial Park
Yavne, Israel

Establishment Registration Number: 9616256

Owner/operator number: 9040071

K052442

2/2

Predicate Devices

Radiancy SkinStation Systems

Cooltouch Prima IPL system (predicate for Cutera Pulsed Light Hand Piece)

Candela, Inc. C-Beam dye laser

Lumenis, Inc., BClear™ lamp

CureLight, Ltd., MultiClear lamp

MSQ ("M2") Ltd. Lovely II IPL UV lamp

Intended Use / Indications for Use

The SkinStation® is intended to provide phototherapeutic light to the body and is generally indicated to treat dermatological conditions. The SkinStation is specifically indicated for hair removal and treatment of vascular and pigmented lesions, mild to moderate inflammatory acne vulgaris which includes pustular acne, in patients with Fitzpatrick skin types I-VI, and mild to moderate psoriasis in patients with Fitzpatrick skin types I-VI.

Technological Characteristics

The Skin Station that is the subject of this 510(k) notice is the exact same device as the cleared Skin Station except for the addition of a light unit assembly specifically for the treatment of psoriasis in patients with Fitzpatrick skin types I - VI.

Substantial Equivalence

The Radiancy SkinStation, as modified, has the same intended use and very similar indications for use, principles of operation and technological characteristics as the cleared Radiancy SkinStation, and the Cooltouch Prima IPL system, Candela, Inc. C-Beam dye laser, Lumenis, Inc., BClear™ lamp, CureLight, Ltd., MultiClear lamp and the MSQ ("M2") Ltd. Lovely II IPL UV lamp. The new psoriasis indication for use is based upon the **indications for use** for two already cleared predicate pulsed light device systems PRIMA IPL and the Cutera, Inc. Cutera Optional Pulsed Light Hand Piece (PRIMA is the predicate device for the cleared Cutera Optional Pulsed Light Hand Piece Family (K050047) [Attachment 4]. The minor differences between the Radiancy SkinStation and the predicates do not raise new issues of safety and effectiveness. Thus, the Radiancy SkinStation is substantially equivalent.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JAN 26 2006

Ms. Margaret R. Fourte
Director, Clinical and Regulatory Affairs
Radiancy, Inc.
40 Ramland Road South, Suite 10
Orangeburg, New York 10962

Re: K052442
Trade/Device Name: Radiancy SkinStation® with Modified Light Unit Assembly for Psoriasis
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: December 22, 2005
Received: December 23, 2005

Dear Ms. Fourte:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,



Mark N. Melkerson
Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Form

510(k) Number (if known): K052442

Device Name: **Radiancy SkinStation® with Modified Light Unit Assembly for Psoriasis**

Indications for Use:

The SkinStation® is intended to provide phototherapeutic light to the body and is generally indicated to treat dermatological conditions. The SkinStation is specifically indicated for hair removal and treatment of vascular and pigmented lesions, mild to moderate inflammatory acne vulgaris which includes pustular acne, in patients with Fitzpatrick skin types I-VI, and mild to moderate psoriasis in patients with Fitzpatrick skin types I-VI.

Prescription Use __X__ OR Over-The-Counter Use____

(Per 21 C.F.R. 801.109)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number K052442